U.S. markets closed
  • S&P Futures

    4,461.50
    +15.75 (+0.35%)
     
  • Dow Futures

    34,814.00
    +140.00 (+0.40%)
     
  • Nasdaq Futures

    15,367.50
    +48.75 (+0.32%)
     
  • Russell 2000 Futures

    2,255.80
    +11.80 (+0.53%)
     
  • Crude Oil

    75.07
    +1.09 (+1.47%)
     
  • Gold

    1,754.00
    +2.30 (+0.13%)
     
  • Silver

    22.50
    +0.08 (+0.33%)
     
  • EUR/USD

    1.1723
    +0.0005 (+0.05%)
     
  • 10-Yr Bond

    1.4600
    +0.0500 (+3.55%)
     
  • Vix

    17.75
    -0.88 (-4.72%)
     
  • GBP/USD

    1.3668
    -0.0012 (-0.09%)
     
  • USD/JPY

    110.7030
    +0.0180 (+0.02%)
     
  • BTC-USD

    43,893.30
    +1,405.96 (+3.31%)
     
  • CMC Crypto 200

    1,096.53
    -6.53 (-0.59%)
     
  • FTSE 100

    7,051.48
    -26.87 (-0.38%)
     
  • Nikkei 225

    30,310.11
    +61.30 (+0.20%)
     

PhaseBio To Report Fourth Quarter and Full-Year 2018 Financial and Business Results on March 26, 2019

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

MALVERN, Pa. and SAN DIEGO, March 19, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced it will report financial and business results for the fourth quarter and full-year 2018 on March 26, 2019, after the close of the U.S. financial markets.

For more information on PhaseBio and to receive PhaseBio’s press releases, please visit the Investors Section of the company’s website at https://investors.phasebio.com and register for email alerts.

About PhaseBio

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary disorders. The company’s lead development candidate is PB2452, a novel reversal agent for the antiplatelet therapy ticagrelor. PhaseBio is also leveraging its proprietary elastin-like polypeptide (“ELP”) technology platform to develop therapies with the potential for less-frequent dosing and improved pharmacokinetics. PhaseBio’s second product candidate PB1046, which is based on ELP, is a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension.

PhaseBio is located in Malvern, PA and San Diego, CA. For more information, please visit www.phasebio.com.

Investor Contact:
John Sharp
PhaseBio Pharmaceuticals, Inc.
Chief Financial Officer
(610) 981-6506
john.sharp@phasebio.com

Media Contact:
Annie Starr
6 Degrees
(973) 415-8838
astarr@6degreespr.com